Dr. Mezgebe Berhe Some HIV patients now eligible for study at NTIDC Tammye Nash | Managing Editornash@dallasvoice.com Pfizer Inc.
announced over the weekend that the company has expanded enrollment in the company’s ongoing Phase 3 clinical trial of a vaccine for COVID-19 to up to about 40,000 participants, an expansion that allows for “the enrollment of new populations.” For the researchers conducting the Pfizer Phase 3 trials at North Texas Infectious Disease Consultants, that means there is now room in the vaccine trial for certain of the practice’s HIV-positive patients, according to NTIDC’s Dr.
Mezgebe Berhe. “Enrollment in the trial has been proceeding as planned,” according to a press release dated Sept. 12, and the company “expects